Vivos Therapeutics (NASDAQ:VVOS) Trading Up 9.9% – Should You Buy?

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) were up 9.9% on Tuesday . The stock traded as high as $0.54 and last traded at $0.4622. 33,641,816 shares traded hands during trading, an increase of 22,065% from the average session volume of 151,780 shares. The stock had previously closed at $0.4206.

Wall Street Analyst Weigh In

Several analysts recently issued reports on VVOS shares. HC Wainwright dropped their price objective on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a research note on Friday, April 17th. Ascendiant Capital Markets upped their target price on Vivos Therapeutics from $3.00 to $3.10 and gave the company a “buy” rating in a report on Thursday, June 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $2.80.

Vivos Therapeutics Stock Performance

The firm’s 50-day moving average is $0.51 and its 200 day moving average is $1.00. The stock has a market cap of $6.42 million, a PE ratio of -0.22 and a beta of 6.22.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). The company had revenue of $5.14 million for the quarter, compared to analysts’ expectations of $4.35 million. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%. On average, sell-side analysts predict that Vivos Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Vivos Therapeutics

A number of large investors have recently bought and sold shares of VVOS. Acorn Wealth Advisors LLC purchased a new position in shares of Vivos Therapeutics during the 4th quarter worth approximately $30,000. XTX Topco Ltd acquired a new position in shares of Vivos Therapeutics in the second quarter worth $65,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Vivos Therapeutics in the first quarter valued at $28,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Vivos Therapeutics in the second quarter valued at $220,000. Finally, DRW Securities LLC increased its position in Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares in the last quarter. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.